Details for Patent: 7,951,797

Which drugs does patent 7,951,797 protect, and when does it expire?

Patent 7,951,797 protects BELSOMRA and is included in one NDA.

This patent has fifty-seven patent family members in thirty-six countries.

Summary for Patent: 7,951,797

Title:	Substituted diazepan orexin receptor antagonists
Abstract:	The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Inventor(s):	Breslin; Michael J. (Drexel Hill, PA), Coleman; Paul J. (Wallingford, PA), Cox; Christopher D. (Harleysville, PA)
Assignee:	Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:	11/998,812
Patent Claim Types: see list of patent claims	Compound; Composition; Use;

Drugs Protected by US Patent 7,951,797

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-001	Aug 13, 2014		RX	Yes	No			Y	Y		TREATMENT OF INSOMNIA
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-002	Aug 13, 2014		RX	Yes	No			Y	Y		TREATMENT OF INSOMNIA
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-003	Aug 13, 2014		RX	Yes	No			Y	Y		TREATMENT OF INSOMNIA
Merck Sharp Dohme	BELSOMRA	suvorexant	TABLET;ORAL	204569-004	Aug 13, 2014		RX	Yes	Yes			Y	Y		TREATMENT OF INSOMNIA

International Family Members for US Patent 7,951,797

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	063979
Argentina	088881
Australia	2007328267
Australia	2010249269
Brazil	PI0719361
Canada	2670892